Skip to main content

Advertisement

Articles

Page 2 of 40

  1. Immunotherapy, especially immune checkpoint inhibition, has provided powerful tools against cancer. We aimed to detect the expression of common immune checkpoints and evaluate their prognostic values in nasoph...

    Authors: Ya-Qin Wang, Yu Zhang, Wei Jiang, Yu-Pei Chen, Shuo-Yu Xu, Na Liu, Yin Zhao, Li Li, Yuan Lei, Xiao-Hong Hong, Ye-Lin Liang, Jun-Yan Li, Lu-Lu Zhang, Jing-Ping Yun, Ying Sun, Ying-Qin Li…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:298

    Content type: Research article

    Published on:

  2. Analysis of deficiency in DNA mismatch repair (dMMR) is currently considered a standard molecular test in all patients with colorectal cancer (CRC) for its implications in screening, prognosis and prediction o...

    Authors: Fotios Loupakis, Giulia Maddalena, Ilaria Depetris, Sabina Murgioni, Francesca Bergamo, Angelo Paolo Dei Tos, Massimo Rugge, Giada Munari, Andrew Nguyen, Christopher Szeto, Vittorina Zagonel, Sara Lonardi and Matteo Fassan

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:297

    Content type: Case report

    Published on:

  3. Adoptive transfer of autologous T-lymphocytes transduced with a high affinity NY-ESO-1-reactive T-cell receptor (NY-ESO-1c259 T-cells) has emerged as a promising therapeutic strategy for patients with refractory ...

    Authors: Jocelyn Joseph, Michael J. Nathenson, Van Anh Trinh, Karan Malik, Erica Nowell, Kristen Carter, Shiao-Pei Weathers, George D. Demetri, Dejka Araujo and Anthony P. Conley

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:296

    Content type: Case report

    Published on:

  4. While cancer immunotherapies including checkpoint blockade antibodies, adoptive T cell therapy, and even some vaccines have given rise to major clinical responses with durability in many cases, a subset of pat...

    Authors: Jonathan A. Trujillo, Jason J. Luke, Yuanyuan Zha, Jeremy P. Segal, Lauren L. Ritterhouse, Stefani Spranger, Karen Matijevich and Thomas F. Gajewski

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:295

    Content type: Research article

    Published on:

  5. The efficacy of PD-(L)1 blockade depends on the composition of the tumor immune microenvironment (TIME) and is generally higher in tumors with pre-existing cytotoxic T cells (CTL) than in those with low CTL nu...

    Authors: Anne Catherine Bretz, Ulrike Parnitzke, Kerstin Kronthaler, Tobias Dreker, René Bartz, Frank Hermann, Astrid Ammendola, Tanja Wulff and Svetlana Hamm

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:294

    Content type: Research article

    Published on:

  6. The most common metastatic lesions of prostate cancer are in bone and can be classified into three distinct pathology subtypes: lytic, blastic, and an indeterminate mixture of both. We investigated a cohort of...

    Authors: Claire L. Ihle, Meredith D. Provera, Desiree M. Straign, E. Erin Smith, Susan M. Edgerton, Adrie Van Bokhoven, M. Scott Lucia and Philip Owens

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:293

    Content type: Short report

    Published on:

  7. Immune checkpoint inhibitors (CPIs) are effective against a variety of malignancies but can be limited by inflammatory toxicities such as enterocolitis. Enterocolitis is typically treated with systemically act...

    Authors: Michael S. Hughes, Gabriel E. Molina, Steven T. Chen, Hui Zheng, Vikram Deshpande, Riley Fadden, Ryan J. Sullivan and Michael Dougan

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:292

    Content type: Research article

    Published on:

  8. The tremendous clinical success of immune checkpoint inhibition (ICI), particularly targeting the programmed cell death protein 1 (PD-1)/programmed death-ligand 1/2 (PD-L1/2) pathway, has resulted in applicati...

    Authors: Catherine T. Le and William J. Murphy

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:291

    Content type: Commentary

    Published on:

  9. The peculiar multiple myeloma microenvironment, characterized by up-regulated levels of several inflammatory chemokines, including the CXCR3 receptor ligands CXCL9 and CXCL10, limits NK cell positioning into t...

    Authors: Valentina Bonanni, Fabrizio Antonangeli, Angela Santoni and Giovanni Bernardini

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:290

    Content type: Research article

    Published on:

  10. The introduction of immune checkpoint inhibitors has led to a survival benefit in patients with advanced melanoma; however data on the adoption of immunotherapy in the community are scarce.

    Authors: Marieke J. Krimphove, Karl H. Tully, David F. Friedlander, Maya Marchese, Praful Ravi, Stuart R. Lipsitz, Kerry L. Kilbridge, Adam S. Kibel, Luis A. Kluth, Patrick A. Ott, Toni K. Choueiri and Quoc-Dien Trinh

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:289

    Content type: Research article

    Published on:

  11. The tumor microenvironment (TME) combines features of regulatory cytokines and immune cell populations to evade the recognition by the immune system. Myeloid-derived suppressor cells (MDSC) comprise population...

    Authors: Philipp Metzger, Sabrina V. Kirchleitner, Michael Kluge, Lars M. Koenig, Christine Hörth, Carlotta A. Rambuscheck, Daniel Böhmer, Julia Ahlfeld, Sebastian Kobold, Caroline C. Friedel, Stefan Endres, Max Schnurr and Peter Duewell

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:288

    Content type: Research article

    Published on:

  12. Sensitivity to immune checkpoint inhibitor (ICPI) therapy is governed by a complex interplay of tumor and host-related determinants. Epidemiological studies have highlighted that exposure to antibiotic therapy...

    Authors: David J. Pinato, Daria Gramenitskaya, Daniel M. Altmann, Rosemary J. Boyton, Benjamin H. Mullish, Julian R. Marchesi and Mark Bower

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:287

    Content type: Commentary

    Published on:

  13. Immune-checkpoint inhibitors (ICIs) emerged as a novel class of drugs for the treatment of a broad spectrum of malignancies. ICIs can produce durable antitumor responses but they are also associated with immun...

    Authors: Yinghong Zhai, Xiaofei Ye, Fangyuan Hu, Jinfang Xu, Xiaojing Guo, Yonglong Zhuang and Jia He

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:286

    Content type: Research article

    Published on:

  14. Following publication of the original article [1], the authors have reported that the following sentence “While of the same IgG1 class as ipilimumab, preclinical data suggests this molecule may have enhanced a...

    Authors: Vaia Florou, Andrew E. Rosenberg, Eric Wieder, Krishna V. Komanduri, Despina Kolonias, Mohamed Uduman, John C. Castle, Jennifer S. Buell, Jonathan C. Trent and Breelyn A. Wilky

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:285

    Content type: Correction

    Published on:

    The original article was published in Journal for ImmunoTherapy of Cancer 2019 7:213

  15. Affinity-optimized T cell receptor (TCR)-engineered lymphocytes targeting tumor antigens can mediate potent antitumor responses in cancer patients, but also bear substantial risks for off-target toxicities. Mo...

    Authors: Minh Ngoc Duong, Efe Erdes, Michael Hebeisen and Nathalie Rufer

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:284

    Content type: Research article

    Published on:

  16. Treatment options for advanced cervical cancer are limited and patients experiencing recurrence after first-line cisplatin-based chemotherapy and bevacizumab have a poor prognosis. A recent phase II study in a...

    Authors: Florence Baettig, Tatjana Vlajnic, Marcus Vetter, Katharina Glatz, Jürgen Hench, Stephan Frank, Michel Bihl, Roberto Lopez, Michael Dobbie, Viola Heinzelmann-Schwarz and Céline Montavon

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:281

    Content type: Case report

    Published on:

  17. The treatment of endometrial cancer (EC), the most common gynecological cancer, is currently hampered by the toxicity of current cytotoxic agents, meaning novel therapeutic approaches are urgently required.

    Authors: Gareth D. Healey, Belen Pan-Castillo, Jezabel Garcia-Parra, Julia Davies, Shaun Roberts, Eilir Jones, Kalyan Dhar, Sarika Nandanan, Nasima Tofazzal, Luke Piggott, Richard Clarkson, Gillian Seaton, Asa Frostell, Tim Fagge, Colin McKee, Lavinia Margarit…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:280

    Content type: Research article

    Published on:

  18. The role of tumor-infiltrating B-cells (TIBs) and intratumorally-produced antibodies in cancer-immunity interactions essentially remains terra incognita. In particular, it remains unexplored how driver mutations ...

    Authors: O. I. Isaeva, G. V. Sharonov, E. O. Serebrovskaya, M. A. Turchaninova, A. R. Zaretsky, M. Shugay and D. M. Chudakov

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:279

    Content type: Research article

    Published on:

  19. The development of immune checkpoint inhibitors has changed the treatment paradigm for advanced cancers across many tumor types. Despite encouraging and sometimes durable responses in a subset of patients, mos...

    Authors: Andrew A. Davis and Vaibhav G. Patel

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:278

    Content type: Short report

    Published on:

  20. Prostate cancer responds poorly to current immunotherapies. Epigenetic therapies such as BET Bromodomain inhibition can change the transcriptome of tumor cells, possibly making them more immunogenic and thus s...

    Authors: Wendy Mao, Ali Ghasemzadeh, Zachary T. Freeman, Aleksandar Obradovic, Matthew G. Chaimowitz, Thomas R. Nirschl, Emily McKiernan, Srinivasan Yegnasubramanian and Charles G. Drake

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:277

    Content type: Research article

    Published on:

  21. Gene-modified autologous T cells expressing NY-ESO-1c259, an affinity-enhanced T-cell receptor (TCR) reactive against the NY-ESO-1-specific HLA-A*02-restricted peptide SLLMWITQC (NY-ESO-1 SPEAR T-cells; GSK 794),...

    Authors: Indu Ramachandran, Daniel E. Lowther, Rebecca Dryer-Minnerly, Ruoxi Wang, Svetlana Fayngerts, Daniel Nunez, Gareth Betts, Natalie Bath, Alex J. Tipping, Luca Melchiori, Jean-Marc Navenot, John Glod, Crystal L. Mackall, Sandra P. D’Angelo, Dejka M. Araujo, Warren A. Chow…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:276

    Content type: Research article

    Published on:

  22. Antibodies targeting programmed death-1 (PD-1) or programmed death-ligand 1 (PD-L1) have shown clinical activity in the treatment of metastatic renal cell carcinoma (mRCC). This phase Ib cohort of the JAVELIN ...

    Authors: Ulka Vaishampayan, Patrick Schöffski, Alain Ravaud, Christian Borel, Julio Peguero, Jorge Chaves, John C. Morris, Nuria Kotecki, Martin Smakal, Dongli Zhou, Silke Guenther, Marcis Bajars and James L. Gulley

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:275

    Content type: Research article

    Published on:

  23. Metastatic TNBC (mTNBC) has a poor prognosis and few treatment options. The anti-PD-L1 antibody atezolizumab demonstrated clinical activity in mTNBC patients with PD-L1-positive tumor-infiltrating immune cells...

    Authors: Luciana Molinero, Yijin Li, Ching-Wei Chang, Sophia Maund, Maureen Berg, Jeanne Harrison, Marcella Fassò, Carol O’Hear, Priti Hegde and Leisha A. Emens

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:274

    Content type: Case report

    Published on:

  24. Following publication of the original article [1], the author reported that the current funding section “Kidney Cancer Association Young Investigator Grant provided funding for this project” should be replaced...

    Authors: Pooja Ghatalia, Jennifer Gordetsky, Fengshen Kuo, Essel Dulaimi, Kathy Q. Cai, Karthik Devarajan, Sejong Bae, Gurudatta Naik, Timothy A. Chan, Robert Uzzo, A. Ari Hakimi, Guru Sonpavde and Elizabeth Plimack

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:273

    Content type: Correction

    Published on:

    The original article was published in Journal for ImmunoTherapy of Cancer 2019 7:139

  25. Diffuse large B-cell lymphoma (DLBCL) harbors somatic hypermutation (SHM) in the immunoglobulin heavy chain and light chain variable region genes, IGHV and IGK/LV. Recent studies have revealed that IGV SHM cre...

    Authors: Zijun Y. Xu-Monette, Jianyong Li, Yi Xia, Beryl Crossley, Robert D. Bremel, Yi Miao, Min Xiao, Thomas Snyder, Ganiraju C. Manyam, Xiaohong Tan, Hongwei Zhang, Carlo Visco, Alexandar Tzankov, Karen Dybkaer, Govind Bhagat, Wayne Tam…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:272

    Content type: Research article

    Published on:

  26. Chimeric antigen receptor-modified (CAR) T-cell immunotherapy is a novel promising therapy for treatment of B-cell malignancy. Cytokine release syndrome (CRS) and infection are the most common adverse events d...

    Authors: Hui Luo, Na Wang, Liang Huang, Xiaoxi Zhou, Jin Jin, Chunrei Li, Di Wang, Bin Xu, Jinhuan Xu, Lijun Jiang, Jue Wang, Yang Cao, Yi Xiao, Qian Zhang, Xia Mao, Songya Liu…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:271

    Content type: Research article

    Published on:

  27. Immunotherapy using checkpoint inhibitors, especially PD-1/PD-L1 inhibitors, has now evolved into the most promising therapy for cancer patients. However, most of these inhibitors are monoclonal antibodies, an...

    Authors: Hao Liu, Zhen Zhao, Li Zhang, Yuanke Li, Akshay Jain, Ashutosh Barve, Wei Jin, Yanli Liu, John Fetse and Kun Cheng

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:270

    Content type: Research article

    Published on:

  28. Thymic epithelial tumors are PD-L1–expressing tumors of thymic epithelial origin characterized by varying degrees of lymphocytic infiltration and a predisposition towards development of paraneoplastic autoimmu...

    Authors: Arun Rajan, Christopher R. Heery, Anish Thomas, Andrew L. Mammen, Susan Perry, Geraldine O’Sullivan Coyne, Udayan Guha, Arlene Berman, Eva Szabo, Ravi A. Madan, Leomar Y. Ballester, Stefania Pittaluga, Renee N. Donahue, Yo-Ting Tsai, Lauren M. Lepone, Kevin Chin…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:269

    Content type: Research article

    Published on:

  29. The aim of this study is to profile the cytokines and immune cells of body fluid from metastatic gastric cancer (mGC), and evaluate the potential role as a prognostic factor and the feasibility as a predictive...

    Authors: Hyung Soon Park, Woo Sun Kwon, Sejung Park, Eunji Jo, So Jung Lim, Choong-kun Lee, Jii Bum Lee, Minkyu Jung, Hyo Song Kim, Seung-Hoon Beom, Jun Yong Park, Tae Soo Kim, Hyun Cheol Chung and Sun Young Rha

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:268

    Content type: Research article

    Published on:

  30. Hepatocellular carcinoma (HCC) is the third leading cause of cancer deaths worldwide and confers a poor prognosis. Beyond standard systemic therapy with multikinase inhibitors, recent studies demonstrate the p...

    Authors: Bridget P. Keenan, Lawrence Fong and Robin K. Kelley

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:267

    Content type: Review

    Published on:

  31. Nivolumab, a programmed death-1 (PD-1) inhibitor, is an immune checkpoint inhibitor particularly used in the treatment of malignant melanoma, non-small cell lung cancer and renal cell carcinoma. Immune-related...

    Authors: Anastasia Saade, Audrey Mansuet-Lupo, Jennifer Arrondeau, Constance Thibault, Mariana Mirabel, François Goldwasser, Stéphane Oudard and Laurence Weiss

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:266

    Content type: Case report

    Published on:

    The Correction to this article has been published in Journal for ImmunoTherapy of Cancer 2019 7:335

  32. The interplay between the immune system and tumor progression is well recognized. However, current human breast cancer immunophenotyping studies are mostly focused on primary tumors with metastatic breast canc...

    Authors: Li Zhu, Jessica L. Narloch, Sayali Onkar, Marion Joy, Gloria Broadwater, Catherine Luedke, Allison Hall, Rim Kim, Katherine Pogue-Geile, Sarah Sammons, Naema Nayyar, Ugonma Chukwueke, Priscilla K. Brastianos, Carey K. Anders, Adam C. Soloff, Dario A. A. Vignali…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:265

    Content type: Short report

    Published on:

  33. Immune checkpoint inhibitors (ICIs) have achieved impressive success in different cancer types, yet responses vary and predictive biomarkers are urgently needed. Growing evidence points to a link between DNA m...

    Authors: Hao-Xiang Wu, Yan-Xing Chen, Zi-Xian Wang, Qi Zhao, Ming-Ming He, Ying-Nan Wang, Feng Wang and Rui-Hua Xu

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:264

    Content type: Research article

    Published on:

  34. The implementation of immune checkpoint inhibitors to the oncology clinic signified a new era in cancer treatment. After the first indication of melanoma, an increasing list of additional cancer types are now ...

    Authors: Thorbald van Hall, Pascale André, Amir Horowitz, Dan Fu Ruan, Linda Borst, Robert Zerbib, Emilie Narni-Mancinelli, Sjoerd H. van der Burg and Eric Vivier

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:263

    Content type: Review

    Published on:

  35. Immune checkpoint inhibitors have improved clinical outcomes including survival in several malignancies but have also been associated with a range of immune-related adverse events (irAEs). Neurological irAEs a...

    Authors: Catherine A. Gao, Urs M. Weber, Aldo J. Peixoto and Sarah A. Weiss

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:262

    Content type: Case report

    Published on:

  36. Standard treatment of oropharyngeal squamous cell carcinoma (OPSCC) is associated with high morbidity, whereas immunotherapeutic approaches using PD-1:PD-L1 checkpoint blockade only show moderate response rate...

    Authors: Kamila Hladíková, Vladimír Koucký, Jan Bouček, Jan Laco, Marek Grega, Miroslav Hodek, Michal Zábrodský, Milan Vošmik, Kateřina Rozkošová, Hana Vošmiková, Petr Čelakovský, Viktor Chrobok, Aleš Ryška, Radek Špíšek and Anna Fialová

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:261

    Content type: Research article

    Published on:

  37. The tumor microenvironment exists in a state of dynamic equilibrium, in which a balance of agonist and antagonist signals govern the anti-tumor immune responses. Previous studies have shown that chemotherapy c...

    Authors: Tae Heung Kang, Chih-Ping Mao, Young Seob Kim, Tae Woo Kim, Andrew Yang, Brandon Lam, Ssu-Hsueh Tseng, Emily Farmer, Yeong-Min Park and Chien-Fu Hung

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:260

    Content type: Short report

    Published on:

  38. Natural killer (NK) cells are important anti-tumor cells of our innate immune system. Their anti-cancer activity is mediated through interaction of a wide array of activating and inhibitory receptors with thei...

    Authors: B. Martín-Antonio, G. Suñe, A. Najjar, L. Perez-Amill, A. Antoñana-Vildosola, M. Castella, S. León, M. Velasco-de Andrés, F. Lozano, E. Lozano, C. Bueno, J. M. Estanyol, C. Muñoz-Pinedo, S. N. Robinson and A. Urbano-Ispizua

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:259

    Content type: Research article

    Published on:

  39. Prostate cancer (PCa) is one of the main causes of cancer-related death in men. In the present immunotherapy era, several immunotherapeutic agents have been evaluated in PCa with poor results, possibly due to its...

    Authors: Giuseppe Schepisi, Maria Concetta Cursano, Chiara Casadei, Cecilia Menna, Amelia Altavilla, Cristian Lolli, Claudio Cerchione, Giovanni Paganelli, Daniele Santini, Giuseppe Tonini, Giovanni Martinelli and Ugo De Giorgi

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:258

    Content type: Review

    Published on:

  40. Several mechanisms are present in the tumor microenvironment (TME) to impair cytotoxic T cell responses potentially able to control tumor growth. Among these, the accumulation of adenosine (Ado) contributes to...

    Authors: Beatris Mastelic-Gavillet, Blanca Navarro Rodrigo, Laure Décombaz, Haiping Wang, Giuseppe Ercolano, Rita Ahmed, Leyder Elena Lozano, Angela Ianaro, Laurent Derré, Massimo Valerio, Thomas Tawadros, Patrice Jichlinski, Tu Nguyen-Ngoc, Daniel E. Speiser, Grégory Verdeil, Nicolas Gestermann…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:257

    Content type: Research article

    Published on:

  41. Programmed cell death 1 inhibitors have revolutionized therapy for cancer by their outstanding effectiveness. However, they may cause adverse effects, among which inflammatory myopathy is one of the most disab...

    Authors: Shiro Matsubara, Morinobu Seki, Shigeaki Suzuki, Takashi Komori and Mikio Takamori

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:256

    Content type: Short report

    Published on:

  42. Pancreatic ductal adenocarcinoma (PDAC) is a highly devastating disease with an overall 5-year survival rate of less than 8%. New evidence indicates that PDAC cells release pro-inflammatory metabolites that in...

    Authors: Rosalinda Trovato, Alessandra Fiore, Sara Sartori, Stefania Canè, Rosalba Giugno, Luciano Cascione, Salvatore Paiella, Roberto Salvia, Francesco De Sanctis, Ornella Poffe, Cristina Anselmi, Francesca Hofer, Silvia Sartoris, Geny Piro, Carmine Carbone, Vincenzo Corbo…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:255

    Content type: Research article

    Published on:

  43. In melanoma, there is no companion diagnostic test to predict response to programmed cell death 1 (PD-1) axis immune checkpoint inhibitor (ICI) therapy. In the adjuvant setting, only one in five patients may b...

    Authors: Swati Gupta, Leena McCann, Yvonne G. Y. Chan, Edwin W. Lai, Wei Wei, Pok Fai Wong, James W. Smithy, Jodi Weidler, Brian Rhees, Michael Bates, Harriet M. Kluger and David L. Rimm

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:254

    Content type: Research article

    Published on:

  44. Adrenocortical carcinoma (ACC) is a rare malignancy without good treatment options. There are limited data about the use of immunotherapy in ACC. We investigated the efficacy and safety of pembrolizumab in pat...

    Authors: Mouhammed Amir Habra, Bettzy Stephen, Matthew Campbell, Kenneth Hess, Coya Tapia, Mingxuan Xu, Jordi Rodon Ahnert, Camilo Jimenez, Jeffrey E. Lee, Nancy D. Perrier, Russell R. Boraddus, Shubham Pant, Vivek Subbiah, David S. Hong, Abdulrazzak Zarifa, Siqing Fu…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:253

    Content type: Research article

    Published on:

  45. The US is experiencing an epidemic of HPV+ oropharyngeal cancers (OPC), the rates and burden of which now exceed that for cervical cancer. Immunotherapy targeting programmed death 1 (PD-1) on tumor-infiltrating l...

    Authors: Stephanie Dorta-Estremera, Venkatesh L. Hegde, Ravaen B. Slay, Rachel Sun, Ananta V. Yanamandra, Courtney Nicholas, Sita Nookala, Gloria Sierra, Michael A. Curran and K. Jagannadha Sastry

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:252

    Content type: Research article

    Published on:

  46. Immune checkpoint inhibitors (ICIs) confer a survival benefit in many cancer types. Given that the survival outcome for cancer of unknown primary site (CUP) remains poor, we investigated the potential of CUP f...

    Authors: Koji Haratani, Hidetoshi Hayashi, Takayuki Takahama, Yasushi Nakamura, Shuta Tomida, Takeshi Yoshida, Yasutaka Chiba, Takahiro Sawada, Kazuko Sakai, Yoshihiko Fujita, Yosuke Togashi, Junko Tanizaki, Hisato Kawakami, Akihiko Ito, Kazuto Nishio and Kazuhiko Nakagawa

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:251

    Content type: Research article

    Published on:

  47. Antibody-drug conjugates (ADCs) targeting the RON receptor, a tumorigenic factor contributing to cancer malignancy, has been considered as a novel strategy for cancer therapy. Here we describe a humanized anti...

    Authors: Xiang-Min Tong, Liang Feng, Sreedhar Reddy Suthe, Tian-Hao Weng, Chen-Yu Hu, Yi-Zhi Liu, Zhi-Gang Wu, Ming-Hai Wang and Hang-Ping Yao

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:250

    Content type: Research article

    Published on:

Annual Journal Metrics

Advertisement